Olema Pharmaceuticals: Financial Headwinds Meet Billion-Dollar Market Potential - Experts See Up to 400% Price Potential!

Olema Pharmaceuticals (OLMA) ended the second quarter with cash equivalents amounting to $461.1 million but simultaneously recorded an increased net loss. The focus is on the development of the lead compound Palazestrant, for which the Phase 3 study OPERA-01 has recently completed recruitment, and data are expected in early 2027. Analysts are predominantly optimistic following the quarterly report presentation, led by a buy recommendation from Citi with a price target of $59. Business Model and Quarterly Balance in Focus Olema Pharmaceuticals...